Clinical trials: ctDNA Monitoring
- Condition ctDNA Monitoring
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification
Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer
Microlyvaq™ is a first-line, non-randomized, two-arm clinical trial in advanced non-small cell lung cancer (NSCLC). In both arms, patients receive a personalized multi-epitope vaccine (Microlyvaq™) on top of standard-of-care…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer
- Trial name
- Microlyvaq™ (NCT07285434)
- Testing
- Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic)
- Where
- Greece
- Volunteers
- 90 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Metastatic Cancers
Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.
The goal of this observational study is to investigate the real-world treatment landscape of patients with metastatic cancer and determine the role of ctDNA in monitoring treatment response in patients with metastatic cancer who…
- Trial name
- GS_ZKM (NCT06929910)
- Where
- Vietnam
- Volunteers
- 200 people
- Sponsor
- Gene Solutions